Therapeutic Effects of 1% Cyclosporin A Eyedrops on Herpetic Stromal Keratitis

Kwang-Hoon Lee; Chang-Soo Park; Sang-Woo Juhng; Je-Moon Woo; Yeoung-Geol Park; Kyung-Chul Yoon

doi:10.4068/cmj.2008.44.3.157

Journal List > Chonnam Med J > v.44(3) > 1017888

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Park, Juhng, Woo, Park, and Yoon: Therapeutic Effects of 1% Cyclosporin A Eyedrops on Herpetic Stromal Keratitis

Original Article

Chonnam Medical Journal

Chonnam Medical Journal 2008; 44(3): 157-161.

Published online: 18 December 2008

DOI: https://doi.org/10.4068/cmj.2008.44.3.157

Therapeutic Effects of 1% Cyclosporin A Eyedrops on Herpetic Stromal Keratitis

Kwang-Hoon Lee, Chang-Soo Park^1,³, Sang-Woo Juhng^1,³, Je-Moon Woo², Yeoung-Geol Park³, Kyung-Chul Yoon³

Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Korea.

¹Department of Pathology, Chonnam National University Medical School and Hospital, Gwangju, Korea.

²Department of Ophthalmology, Ulsan Hospital, College of Medicine, Ulsan University, Ulsan, Korea.

³Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.

Corresponding author (kcyoon@jnu.ac.kr)

Accepted 31 October 2008

Abstract

We evaluated the therapeutic effects of topical administration of 1% cyclosporin A on herpetic stromal keratitis. Sixteen eyes of 16 patients with non-necrotizing herpetic stromal keratitis were divided into two groups according to the use of topical cyclosporin A and retrospectively reviewed. Symptom duration, visual acuity, stromal haziness, and time to improvement of stromal inflammation were analyzed. Eight eyes of 8 patients were treated with 1% cyclosporin A eyedrops in addition to conventional medication and other 8 patients (8 eyes) with conventional treatment only. There were no differences in pre-treatment symptom duration, visual acuity and stromal haziness between two groups. In cyclosporin A treatment group, visual acuity (p=0.018) and stromal haziness (p=0.034) were significantly improved after treatment. There were no differences in time to improvement of stromal inflammation (p=0.798) and post-treatment visual acuity (p=0.234) between two groups, but post-treatment stromal haziness (p=0.038) significantly improved in cyclosporin A treatment group than in conventional treatment group. Topical cyclosporin A may be effectively used in treatment of herpetic stromal keratitis for reducing stromal haziness.

Keywords: Cyclosporine, Herpes simplex keratitis, Administration, Topical

Figures and Tables

Fig. 1

Patient No. 6. (A) Preoperative anterior segment photograph showing generalized stromal inflammation involving the central cornea. (B) Four months after treatment, the stromal inflammation improved with mild haziness.

Table 1

Case series of patients with herpes simplex virus stromal keratitis who were treated with topical 1% cyclosporin A

^*VA, visual acuity; ^†SH, stromal haziness; ^‡FU, follow up.

Table 2

Case series of patients with herpes simplex virus stromal keratitis who were treated with conventional medication

^*VA, visual acuity; ^†SH, stromal haziness; ^‡FU, follow up.

References

1. Holland EJ, Brilakis HS, Schwartz GS. Krachmer JH, Mannis MJ, Holland EJ, editors. Herpes simplex keratitis. Cornea. 2005. 2nd ed. St. Louis: Mosby;1043–1074.

2. Keadle TL, Morris JL, Pepose JS, Stuart PM. CD4⁺ and CD8⁺ cells are key participants in the development of recurrent herpetic stromal keratitis in mice. Microb Pathog. 2002. 32:255–262.

3. Newell CK, Martin S, Sendele D, Mercadal CM, Rouse BT. Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology. J Virol. 1989. 63:769–775.

4. Thomas J, Gangappa S, Kanangat S, Rouse BT. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis. J Immunol. 1997. 158:1383–1391.

5. Bauer D, Mrzyk S, van Rooijen N, Steuhl KP, Heiligenhaus A. Macrophage-depletion influences the course of murin HSK-1 keratitis. Curr Eye Res. 2000. 20:45–53.

6. Gangappa S, Deshpande SP, Rouse BT. Bystander activation of CD4 (+) T cells can represent an exclusive means of immunopathology in a virus infection. Eur J Immunol. 1999. 29:3674–3682.

7. Heiligenhaus A, Bauer D, Zheng M, Mrzyk S, Steuhl KP. CD4⁺ T-cell type 1 and type 2 cytokines in the HSK-1 infected cornea. Graefes Arch Clin Exp Ophthalmol. 1999. 237:399–406.

8. Doymaz MZ, Rouse BT. Herpetic stromal keratitis: an immunopathologic disease mediated by CD4+ T lymphocytes. Invest Ophthalmol Vis Sci. 1992. 33:2165–2173.

9. Hendricks RL, Tumpey TM, Finnegan A. IFN-gamma and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice. J Immunol. 1992. 149:3023–3028.

10. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol. 2005. 89:1363–1367.

11. Hernández GL, Volpert OV, Iñiguez MA, Lorenzo E, Martinez-Martinez S, Grau R, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med. 2001. 193:607–620.

12. Sall K, Stevenson OD, Mondorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000. 107:631–639.

13. Avunduk AM, Avunduk MC, Erdöl H, Kapicioglu Z, Akyol N. Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica. 2001. 215:290–293.

14. Akpek EK, Dart JK, Watson S, Christen W, Dursun D, Yoo S, et al. A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004. 111:476–482.

15. Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999. 237:435–438.

16. Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol. 2006. 141:771–772.

17. Gündüz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 1997. 29:405–408.

18. Yoon KC, Heo H, Kang IS, Lee MC, Kim KK, Park SH, et al. Effect of topical cyclosporine A on herpetic stromal keratitis in a mouse model. Cornea. 2008. 27:454–460.

19. Heiligenhaus A, Bauer D, Meller D, Steuhl KP, Tseng SC. Improvement of HSV-1 necrotizing keratitis with amniotic membrane transplantation. Invest Ophthalmol Vis Sci. 2001. 42:1969–1974.

20. Shi W, Chen M, Xie L. Amniotic membrane transplantation combined with antiviral and steroid therapy for herpes necrotizing stromal keratitis. Ophthalmology. 2007. 114:1476–1481.

21. Wilhelmus KR, Gee L, Hauck WW, Kurinij N, Dawson CR, Jones DB, et al. Herpetic eye disease study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994. 101:1883–1895.

22. Nussenblatt RB, Palestine AG. Cyclosporin: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986. 31:159–169.

23. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A. Background, immunology, and pharmacology. Cornea. 1990. 9:184–195.

24. Vahlne A, Larsson RA, Horal P, Ahlmén J, Svennerholm B, Gronowitz JS, et al. Inhibition of herpes simplex virus production in vitro by cyclosporine A. Arch Virol. 1992. 122:61–75.

25. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppress hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Trunspl. 2006. 12:51–57.

TOOLS

Similar articles